AMENDMENT NO. 1 TO TRANSACTION BONUS AGREEMENTTransaction Bonus Agreement • January 18th, 2013 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
THIS AMENDMENT NO. 1 TO TRANSACTION BONUS AGREEMENT (“Amendment”) is entered into this 28th day of December, 2012 (the “Effective Date”), by and between ANIP Acquisition Company (the “Company”) and Charlotte Arnold (the “Executive”).
Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions are marked: [***]...Master Product Development and Collaboration Agreement • January 18th, 2013 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This MASTER PRODUCT DEVELOPMENT AND COLLABORATION AGREEMENT is made as of the 11th day of July 2011, by and among ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“ANI”), having a place of business at 210 Main Street West, Baudette, MN 56623 and RiconPharma LLC, a limited liability company having its principal office at 100 Ford Road, Suite #9, Denville, NJ 07834 (“RiconPharma”). ANI and RiconPharma may each be referred to herein individually as a “Party” and collectively as the “Parties.”
